Global Information
회사소개 | 문의 | 비교리스트

호지킨 림프종 : 역학 예측(-2029년)

Hodgkin Lymphoma - Epidemiology Forecast to 2029

리서치사 GlobalData
발행일 2020년 06월 상품 코드 944087
페이지 정보 영문 44 Pages
가격
US $ 3,995 ₩ 4,709,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,990 ₩ 9,418,000 PDF by E-mail (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 11,985 ₩ 14,127,000 PDF by E-mail (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


호지킨 림프종 : 역학 예측(-2029년) Hodgkin Lymphoma - Epidemiology Forecast to 2029
발행일 : 2020년 06월 페이지 정보 : 영문 44 Pages

호지킨 림프종(HL)은 림프계에 영향을 미치는 암성 상태이며, 아동과 성인 모두에서 발생합니다. HL은 림프구로 불리는 백혈구의 비정상적 성장으로부터 시작되어 림프계를 넘어 퍼지며, 신체의 면역계를 해치는 희귀 질환입니다. HL은 cHL(고전적 호지킨 림프종)과 NLPHL(결절성 림프구 우위형 호지킨 림프종)의 2개 주요 그룹으로 분류됩니다. cHL은 또한 아류형, 즉 결절 경화형, 혼합 세포형, 림프구 풍부형 및 림프구 감소형으로 분류됩니다. 고전적 HL은 가장 자주 발생하는 HL이며, HL 증례의 거의 95%가 cHL 타입에 속하고 있습니다. 2019년에는 주요 8개 시장에서 24,885건의 HL 발생 사례가 진단되었습니다. 이것은 0.99%의 연간 성장률(AGR)로 2029년까지 27,134건으로 증가할 것으로 예상됩니다.

세계 주요 8개 시장(미국, 프랑스, 독일, 이탈리아, 스페인, 영국, 일본, 중국 도시)의 호지킨 림프종(HL) 동향에 대해 조사했으며, 부문별(질환 분류, 성별, 연령, 암 병기 등) 10년간 역학 예측을 제공합니다.

제1장 목차

제2장 호지킨 림프종 : 주요 요약

  • 촉매
  • 관련 보고서
  • 향후 보고서

제3장 역학

  • 질환 배경
  • 위험인자와 병존 질환
  • 세계 및 역사적 동향
  • 예측 조사 방법
    • 소스
    • 사용되지 않은 소스
    • 예측 가정과 방법
  • 호지킨 림프종 역학 예측
    • 호지킨 림프종 진단 건수
    • 고전적 호지킨 림프종 진단 건수
    • 고전적 호지킨 림프종 진단 건수 : 연령별
    • 고전적 호지킨 림프종 진단 건수 : 성별
    • 고전적 호지킨 림프종 진단 건수 : 암 병기별
    • 고전적 호지킨 림프종 진단 건수 : 암 아류형별
    • 고전적 호지킨 림프종 5개년 유병 건수
    • 결절성 림프구 우위형 호지킨 림프종 진단 건수
  • 논의
    • 역학 예측 인사이트
    • COVID-19의 영향
    • 분석 제한
    • 분석 강점

제4장 부록

KSM 20.07.10

List of Tables

List of Tables

  • Table 1: Summary of Newly Added Data Types and Countries
  • Table 2: Summary of Updated Data Types
  • Table 3: HL Cancer Stages
  • Table 4: Risk Factors and Comorbidities for HL

List of Figures

List of Figures

  • Figure 1: 8MM, Diagnosed Incident Cases of cHL, Both Sexes, All Ages, 2019 and 2029
  • Figure 2: 8MM, Diagnosed Incidence Rates of cHL, All Ages, Both Sexes, Cases per 100,000 Population, 2009-2029
  • Figure 3: Sources Used for Diagnosed Incident Cases of HL, cHL, and NLPHL
  • Figure 4: Sources Used for Diagnosed Incident Cases of cHL by Stage
  • Figure 5: Sources Used for Diagnosed Incident Cases of cHL Subtypes
  • Figure 6: Sources Used for Five-Year Diagnosed Prevalent Cases of cHL
  • Figure 7: 8MM, Diagnosed Incident Cases of HL, Both Sexes, All Ages, N, 2019
  • Figure 8: 8MM, Diagnosed Incident Cases of cHL, Both Sexes, All Ages, N, 2019
  • Figure 9: 8MM, Age-Specific Diagnosed Incident Cases of cHL, Both Sexes, N, 2019
  • Figure 10: 8MM, Sex-Specific Diagnosed Incident Cases of cHL, All Ages, N, 2019
  • Figure 11: 8MM, Diagnosed Incident Cases of cHL by Cancer Stage at Diagnosis, Both Sexes, All Ages, N, 2019
  • Figure 12: 8MM, Diagnosed Incident Cases of cHL by Cancer Subtypes, Both Sexes, All Ages, N, 2019
  • Figure 13: 8MM, Five-Year Diagnosed Prevalent Cases of cHL, Both Sexes, All Ages, N, 2019 and 2029
  • Figure 14: 8MM, Diagnosed Incident Cases of NLPHL, Both Sexes, All Ages, N, 2019

GlobalData epidemiologists used age- and sex-specific diagnosed incidence and prevalence rates to forecast the diagnosed incident and prevalent cases, taking into account the significant relationship between age and HL incidence. GlobalData epidemiologists applied country-specific incidence rates of HL, wherever available, to each country's population to obtain the number of estimated diagnosed incident cases.

HL is a cancerous condition that affects the lymphatic system and occurs in both children and adults. HL is a rare disease that starts with abnormal growth of the white blood cells, called lymphocytes, and then spreads beyond the lymphatic system and impairs the body's immune system. HL is classified into two main groups-cHL and NLPHL. cHL is further divided into subtypes, namely nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted. The classical form is the most frequently occurring HL, with almost 95% of HL cases belonging to the cHL type.

The following data describes epidemiology of HL cases. In 2019, the 8MM had 24,885 diagnosed incident cases of HL. This is expected to increase to 27,134 diagnosed incident cases by 2029, at an Annual Growth Rate (AGR) of 0.90%. This increase is partly attributed to the moderately rising trend in incidence in the 8MM, combined with underlying demographic changes in the respective markets. In the 8MM, the diagnosed incident cases of cHL will increase from 22,815 cases in 2019 to 24,820 cases in 2029, at an AGR of 0.88%, and the diagnosed incident cases of NLPHL will increase from 2,074 cases in 2019 to 2,314 cases in 2029, at an AGR of 1.18%. The development of more effective therapies, particularly for elderly patients, would improve survival from HL.

Scope

  • Hodgkin Lymphoma (HL) Epidemiology Report provides an overview of the risk factors and global trends of Hodgkin Lymphoma in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Urban China).
  • This report also includes a 10-year epidemiological forecast for the following segmentations in all ages across the 8MM: diagnosed incident cases of HL, classical HL (cHL), Nodular Lymphocyte Predominant HL (NLPHL); diagnosed incident cases of cHL segmented by sex and age, for all ages in 10-year age groups beginning at 0 years and ending at ≥85 years; diagnosed five-year prevalent cases cHL; diagnosed incident cases of cHL by cancer staging (stage I -IV); and diagnosed incident cases of cHL by subtypes (nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted).
  • The HL Epidemiology Report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

  • The HL Epidemiology series will allow you to:
  • Develop business strategies by understanding the trends shaping and driving the global HL, cHL, and NLPHL market.
  • Quantify patient populations in the global HL market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the cHL cancer stages that present the best opportunities for cHL therapeutics in each of the markets covered.
  • Understand magnitude of cHL market by subtypes.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Hodgkin Lymphoma: Executive Summary

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Sources Not Used
    • 3.4.3 Forecast Assumptions and Methods
  • 3.5 Epidemiological Forecast for Hodgkin Lymphoma (2019-2029)
    • 3.5.1 Diagnosed Incident Cases of Hodgkin Lymphoma
    • 3.5.2 Diagnosed Incident Cases of Classical Hodgkin Lymphoma
    • 3.5.3 Age-Specific Diagnosed Incident Cases of Classical Hodgkin Lymphoma
    • 3.5.4 Sex-Specific Diagnosed Incident Cases of Classical Hodgkin Lymphoma
    • 3.5.5 Diagnosed Incident Cases of Classical Hodgkin Lymphoma by Cancer Stage
    • 3.5.6 Diagnosed Incident Cases of Classical Hodgkin Lymphoma by Cancer Subtypes
    • 3.5.7 Five-Year Diagnosed Prevalent Cases of Classical Hodgkin Lymphoma
    • 3.5.8 Diagnosed Incident Cases of Nodular Lymphocyte Predominant Hodgkin Lymphoma
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 COVID-19 Impact
    • 3.6.3 Limitations of Analysis
    • 3.6.4 Strengths of Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 About the Authors
    • 4.2.1 Epidemiologist
    • 4.2.2 Reviewers
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.3 About GlobalData
  • 4.4 Contact Us
  • 4.5 Disclaimer
Back to Top
전화 문의
F A Q